Obstructive Sleep Apnea (OSA) Archives

Jazz Pharmaceuticals completes U.S. divestiture of Sunosi to Axsome Therapeutics

Business, Daytime Sleepiness, Divestments, Narcolepsy, Obstructive Sleep Apnea (OSA), Sleep Disorders, Sleepiness, Therapeutics

Jazz Pharmaceuticals plc completed the divestiture of Sunosi (solriamfetol) in the United States. to Axsome Therapeutics Inc.

Jazz Pharma’s sleep disorder drug gets European panel backing

Narcolepsy, Obstructive Sleep Apnea (OSA), Sleep Disorders

Jazz Pharmaceuticals Plc’s treatment for a form of sleep disorder was recommended for approval by a panel of the European Medicines Agency (EMA).

More than a third of people in the Americas may have obstructive sleep apnea

Obstructive Sleep Apnea (OSA), R&D

Obstructive sleep apnea (OSA) may affect as much as 37 percent of adults in North, Central and South America, according to a review of epidemiological studies.